Triple incretin agonists in diabetes mellitus: retatrutide improves lipid profile and decreases blood pressure

Abstract

This opinion article discusses the emerging potential of retatrutide, a triple incretin agonist, in managing lipid profiles and blood pressure in patients with diabetes mellitus. Retatrutide has shown promise in improving lipid parameters and lower- ing blood pressure in clinical trials, making it a valuable addition to the therapeutic arsenal for diabetes and its associated metabolic disorders. While its precise mechanisms remain to be fully elucidated, the observed benefits highlight its poten- tial to challenge current paradigms in metabolic disease management. The evidence discussed herein, though compelling, requires further validation through larger and more diverse clinical studies.